Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Augustin

Showing results (371-380 of 491) with videos related to

Pageof 50
Sort By:
American Journal of Clinical Dermatology|March 31, 2018
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
American Journal of Clinical Dermatology|January 12, 2017
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
American Journal of Clinical Dermatology|October 20, 2022
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III StudiesLisa Bloudek, Lawrence F Eichenfield, Jonathan I Silverberg, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 11, 2023
Implementing well-being in the management of psoriasis: An expert recommendationRachel Sommer, Ulrich Mrowietz, Kristian Gaarn Du Jardin, et al.
Dermatology and Therapy|September 16, 2024
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with PsoriasisMatthias Augustin, Alice B Gottlieb, Mark Lebwohl, et al.
Journal of Wound Care|February 15, 2020
Efficacy of MMP-inhibiting wound dressings in the treatment of chronic wounds: a systematic reviewJoachim Dissemond, Matthias Augustin, Michael Dietlein, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 7, 2018
What is psoriasis? - Perception and assessment of psoriasis among the German populationRachel Sommer, Ulrich Mrowietz, Marc Alexander Radtke, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 7, 2018
Was ist Schuppenflechte? - Wahrnehmung und Bewertung der Psoriasis in der deutschen BevölkerungRachel Sommer, Ulrich Mrowietz, Marc Alexander Radtke, et al.
Life (Basel, Switzerland)|October 27, 2022
Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response-Data from the German HS Registry HSBestNatalia Kirsten, Frenz Ohm, Kathrin Gehrdau, et al.
Journal of Drugs in Dermatology : JDD|April 14, 2021
Effect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 StudiesMelinda J Gooderham, Boni Elewski, Matthias Augustin, et al.
Pageof 50

Showing results (371-380 of 491) with videos related to

Sort By:
Pageof 50
American Journal of Clinical Dermatology|March 31, 2018
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
American Journal of Clinical Dermatology|January 12, 2017
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
American Journal of Clinical Dermatology|October 20, 2022
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III StudiesLisa Bloudek, Lawrence F Eichenfield, Jonathan I Silverberg, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 11, 2023
Implementing well-being in the management of psoriasis: An expert recommendationRachel Sommer, Ulrich Mrowietz, Kristian Gaarn Du Jardin, et al.
Dermatology and Therapy|September 16, 2024
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with PsoriasisMatthias Augustin, Alice B Gottlieb, Mark Lebwohl, et al.
Journal of Wound Care|February 15, 2020
Efficacy of MMP-inhibiting wound dressings in the treatment of chronic wounds: a systematic reviewJoachim Dissemond, Matthias Augustin, Michael Dietlein, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 7, 2018
What is psoriasis? - Perception and assessment of psoriasis among the German populationRachel Sommer, Ulrich Mrowietz, Marc Alexander Radtke, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 7, 2018
Was ist Schuppenflechte? - Wahrnehmung und Bewertung der Psoriasis in der deutschen BevölkerungRachel Sommer, Ulrich Mrowietz, Marc Alexander Radtke, et al.
Life (Basel, Switzerland)|October 27, 2022
Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response-Data from the German HS Registry HSBestNatalia Kirsten, Frenz Ohm, Kathrin Gehrdau, et al.
Journal of Drugs in Dermatology : JDD|April 14, 2021
Effect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 StudiesMelinda J Gooderham, Boni Elewski, Matthias Augustin, et al.
Pageof 50